| Literature DB >> 24084096 |
Matheus Fernandes Costa-Silva1, Luciana Inácia Gomes, Olindo Assis Martins-Filho, Renata Rodrigues-Silva, Janaína de Moura Freire, Patrícia Flávia Quaresma, Marcelo Antônio Pascoal-Xavier, Tiago Antônio de Oliveira Mendes, Rogéria Serakides, Danielle Alves Gomes Zauli, Ana Carolina Campi-Azevedo, Maria Norma Melo, Célia Maria Ferreira Gontijo, Vanessa Peruhype-Magalhães, Andréa Teixeira-Carvalho.
Abstract
Cutaneous leishmaniasis (CL) is a chronic inflammatory disease caused by dermotropic Leishmania species belonging to the Viannia subgenera, with Leishmania (V.) braziliensis considered the main agent in Brazil. After infection, a local inflammatory process is initiated, inducing the expression of several cytokine/chemokine genes. We evaluated the immunity to CL of patients living in the indigenous community Xakriabá, Minas Gerais state, Brazil, by performing detailed analyses of the mRNA expression of different cytokines and chemokines in CL lesions, considering the time evolution (recent or late). We also studied the profile of the inflammatory infiltrate by histopathological analysis. The histopathological features of recent CL lesions showed an intense inflammatory reaction, characterized by the presence of both mononuclear and polymorphonuclear cells, whereas late CL lesions exhibited a predominance of mononuclear leukocytes. The gene expression of cytokines/chemokines in skin biopsies from the CL group showed higher transcript levels of modulatory (IL10 and TGFB1), anti-inflammatory (IL4), and pro-inflammatory (TNF, IFNG, IL12B, CCL2, CCL3, CCL5, CXCL10) biomarkers in recent lesions than in late lesions. Our findings suggest that differential gene expression of cytokines and chemokines found in skin lesions from CL patients is associated with time evolution of lesions.Entities:
Keywords: Chemokines; Cutaneous leishmaniasis; Cytokines; Gene expression; Localized immune response
Mesh:
Substances:
Year: 2013 PMID: 24084096 DOI: 10.1016/j.molimm.2013.08.008
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407